Baorong Yu1, Xiaojuan Zhang, Guijing Wang. 1. School of Insurance and Economics, University of International Business and Economics, Chaoyang, Beijing, China.
Abstract
BACKGROUND: The control rate for hypertension is unacceptably low worldwide, and poor adherence to medication is a primary reason. OBJECTIVES: To evaluate the impact of full coverage for hypertension drugs on adherence to medication, medical costs, and hypertension control in Shandong Province, China. METHODS: In November 2009, we interviewed 110 hypertensive patients who had been participating in a free medication program since May 2008 and 241 hypertensive patients who were not participating. We used a 1:1 propensity-score matching technique to obtain matched samples of 102 program participants (intervention) and 102 nonparticipants (control). We used univariate analysis to compare patient drug-taking behaviors, medical costs, and hypertension control between the 2 groups. RESULTS: All intervention patients took > 1 drugs for hypertension control and 93% of them took > 3 such drugs, 15 control patients (15%) did not take any, and only 39% took 3 or more (P < .001). Three-fourths (75%) of the intervention patients took the prescribed drugs regularly, whereas 66% of the control group (P = .034) did so. Participation in the program was associated with lower annual out-of-pocket medical costs both overall and for outpatient services (P < .001 for both). CONCLUSIONS: Low-income rural residents in China receiving free drugs had enhanced medication adherence and reduced total medical costs. Providing hypertension drugs at no charge may be a promising strategy for preventing costly cardiovascular events associated with hypertension in China and other parts of the world with growing rates of cardiovascular disease.
BACKGROUND: The control rate for hypertension is unacceptably low worldwide, and poor adherence to medication is a primary reason. OBJECTIVES: To evaluate the impact of full coverage for hypertension drugs on adherence to medication, medical costs, and hypertension control in Shandong Province, China. METHODS: In November 2009, we interviewed 110 hypertensive patients who had been participating in a free medication program since May 2008 and 241 hypertensive patients who were not participating. We used a 1:1 propensity-score matching technique to obtain matched samples of 102 program participants (intervention) and 102 nonparticipants (control). We used univariate analysis to compare patient drug-taking behaviors, medical costs, and hypertension control between the 2 groups. RESULTS: All intervention patients took > 1 drugs for hypertension control and 93% of them took > 3 such drugs, 15 control patients (15%) did not take any, and only 39% took 3 or more (P < .001). Three-fourths (75%) of the intervention patients took the prescribed drugs regularly, whereas 66% of the control group (P = .034) did so. Participation in the program was associated with lower annual out-of-pocket medical costs both overall and for outpatient services (P < .001 for both). CONCLUSIONS: Low-income rural residents in China receiving free drugs had enhanced medication adherence and reduced total medical costs. Providing hypertension drugs at no charge may be a promising strategy for preventing costly cardiovascular events associated with hypertension in China and other parts of the world with growing rates of cardiovascular disease.
Authors: Alice Dragomir; Robert Côté; Louise Roy; Lucie Blais; Lyne Lalonde; Anick Bérard; Sylvie Perreault Journal: Med Care Date: 2010-05 Impact factor: 2.983
Authors: Ali Ahmed; Michael W Rich; Paul W Sanders; Gilbert J Perry; George L Bakris; Michael R Zile; Thomas E Love; Inmaculada B Aban; Michael G Shlipak Journal: Am J Cardiol Date: 2006-12-08 Impact factor: 2.778
Authors: Stephen Jan; Stephen W-L Lee; Jitendra P S Sawhney; Tiong K Ong; Chee Tang Chin; Hyo-Soo Kim; Rungroj Krittayaphong; Vo T Nhan; Yohji Itoh; Yong Huo Journal: Bull World Health Organ Date: 2016-01-28 Impact factor: 9.408
Authors: Dongfeng Gu; Jiang He; Pamela G Coxson; Petra W Rasmussen; Chen Huang; Anusorn Thanataveerat; Keane Y Tzong; Juyang Xiong; Miao Wang; Dong Zhao; Lee Goldman; Andrew E Moran Journal: PLoS Med Date: 2015-08-04 Impact factor: 11.069
Authors: Will Maimaris; Jared Paty; Pablo Perel; Helena Legido-Quigley; Dina Balabanova; Robby Nieuwlaat; Martin McKee Journal: PLoS Med Date: 2013-07-30 Impact factor: 11.069
Authors: Edward S Lee; Rajesh Vedanthan; Panniyammakal Jeemon; Jemima H Kamano; Preeti Kudesia; Vikram Rajan; Michael Engelgau; Andrew E Moran Journal: PLoS One Date: 2016-06-14 Impact factor: 3.240
Authors: Thomas R Frieden; Cherian V Varghese; Sandeep P Kishore; Norman R C Campbell; Andrew E Moran; Raj Padwal; Marc G Jaffe Journal: J Clin Hypertens (Greenwich) Date: 2019-09-23 Impact factor: 3.738